Form 4: Quince Therapeutics Director Luca Benatti Opts for Stock Options Over Cash Retainer

Quince Therapeutics, Inc. Director Luca Benatti was granted 27,000 stock options with an exercise price of $1.09, vesting in one year, as part of his 2025 annual director compensation.

Summary

• Luca Benatti, a Director of Quince Therapeutics, Inc. (QNCX), acquired 27,000 Director Stock Options on June 4, 2025.
• These options have an exercise price of $1.09 per share.
• The options will vest 100% on June 4, 2026, which is the one-year anniversary of the grant date.
• The expiration date for these options is June 4, 2035.
• Mr. Benatti elected to receive these stock options instead of the annual director cash retainer for 2025, as per the issuer's Outside Director Compensation Policy.
• Following this transaction, Mr. Benatti beneficially owns 27,000 derivative securities directly.

Sentiment

Score: 7

Explanation: The filing indicates a standard compensation practice for a director, aligning their interests with the company's long-term performance through equity. This is generally viewed positively as it incentivizes growth and shareholder value.

Positives

• Director Luca Benatti's election to receive stock options instead of cash indicates alignment of his interests with long-term shareholder value.
• The grant of options is part of a standard compensation policy for outside directors, suggesting a structured approach to corporate governance and incentivization.

Risks

• The value of the stock options is dependent on the future performance of Quince Therapeutics' common stock; if the stock price does not exceed the exercise price of $1.09, the options may expire worthless.

Future Outlook

The document indicates a future vesting event for the granted stock options on June 4, 2026, which is contingent on the director's continued service.

Management Comments

• "The shares subject to the option shall vest 100% on the one-year anniversary of the grant date."
• "The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the issuer's Outside Director Compensation Policy."

Industry Context

This Form 4 filing reflects a common practice in the biotechnology and pharmaceutical industries where executive and director compensation often includes equity-based incentives like stock options to align management interests with long-term company performance and shareholder value creation. This is particularly relevant for companies like Quince Therapeutics, which may be in development stages where cash conservation is important.

Comparison to Industry Standards

• The practice of granting stock options to outside directors in lieu of cash retainers is a common compensation strategy across various industries, including biotechnology, to conserve cash and align director incentives with shareholder interests.
• The vesting schedule of 100% on the one-year anniversary of the grant date is a typical arrangement for director equity grants, ensuring continued commitment for at least a year.
• The exercise price of $1.09, likely the fair market value on the grant date, is standard for incentive stock options.

Corporate Governance

Related Party Transactions

• The transaction involves the grant of stock options to a director, Luca Benatti, which is a related party transaction. It is explicitly stated to be provided for under the issuer's Outside Director Compensation Policy, indicating it is a standard, disclosed arrangement.

Stakeholder Impact

• Shareholders: The grant of stock options to a director, especially in lieu of cash, aligns the director's financial interests with those of shareholders, potentially incentivizing long-term value creation and conserving company cash.

Next Steps

• The stock options granted to Luca Benatti are scheduled to vest on June 4, 2026.
• Luca Benatti may exercise his options to acquire common stock at the exercise price of $1.09 per share at any time after vesting and before the expiration date of June 4, 2035.

Key Dates

Keywords

Quince Therapeutics, QNCX, Form 4, SEC filing, stock options, director compensation, equity compensation, insider transaction, Luca Benatti, biotechnology, pharmaceuticals